News - suvorexant


Current filters:


Popular Filters

US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses


The US Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee…

Merck & CoNeurologicalNorth AmericaPharmaceuticalRegulationsuvorexant

FDA accepts Merck & Co's suvorexant; panel backs Novo's Tresiba and Ryzodeg


US drug giant Merck & Co (NYSE: MRK) says that the New Drug Application for suvorexant, the company's…

DegludecDiabetesMerck & CoNeurologicalNorth AmericaNovo NordiskPharmaceuticalRegulationRyzodegsuvorexantTresiba

Merck & Co's suvorexant improved patients' ability to fall asleep and stay asleep


US drug giant Merck & Co (NYSE: MRK) has announced new data from two pivotal Phase III efficacy trials…

Merck & CoNeurologicalPharmaceuticalResearchsuvorexant

Merck & Co confirms NDA filing for suvorexant in 2012


US drugs giant Merck & Co (NYSE: MRK) yesterday provided an update on the development program for suvorexant,…

Merck & CoNeurologicalNorth AmericaPharmaceuticalRegulationResearchsuvorexant

Back to top